About the Journal

Open Access Policy

JPADR is loyal to open access for academic work, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of its articles and to use them for any other lawful purpose. All the articles published in this journal are free to access immediately from the date of publication. We do not charge any fees for any reader to download articles for their own scholarly use.

JPADR operates under the Creative Commons Licence CC-BY-NC-ND. This allows for the reproduction of articles, free of charge, for non-commercial use only, and with the appropriate citation information. All authors publishing with JPADR accept these as the terms of publication.

History of the Journal

The Journal Founded in 2020 by the Global Pharmacovigilance Society to publish articles related the Pharmacovigilance research activities. 

Repository Policy

Journal of Pharmacovigilance and drug research, deposits all published articles in Zenodo. From there it is getting transferred to the National Digital Library of India. Authors can find their published articles on these websites and share them with colleagues.  The assigned DOI numbers and Creative Commons Licence could be found on the Zenodo website.

The JPADR Journal allows authors the use of the final published version of an article (publisher pdf) for self-archiving (author's personal website) and/or archiving in an institutional repository (on a non-profit server) just after the publication of the manuscript on the Journal's website. The published source must be acknowledged and a link to the journal home page must be set.

Authors may download the article as a PDF document and may send copies of the article to colleagues. Journal encourages the author to add their work to Google Scholar, ORCID, Research Gate or any scientific social media for better visibility to the research community.

Peer Review Policy

The received manuscript will undergo an extensive review by the editors of JPADR. Once it passes the preliminary screening, the manuscript will be assigned to one of our editorial board members. The manuscript will be sent to two reviewers for its review. After receiving the comments and decisions from the reviewer, the assigned editor will communicate with the author for any revision. once the author sends the revised manuscript, it may be again sent to the associated review to check whether the author addressed all the comments. when the editor receives the comment from the reviewer, it must be communicated to the editor in chief for the final decision for publication. Once the decision is finalized it would be communicated to the author from the editor in chief.

International Peer Review Process of JPADR

Submission of Paper

The corresponding author should submit the paper to the journal online using our submit menu. The author will be guided through the online process, and be able to track the progress of the manuscript. The system automatically converts the article source files into a single PDF, which is used in the peer-review process.
For further details about the preparation of the files for submission, please browse the complete Guide for Authors.
To enable speedy handling of the manuscript, during the submission process the author must provide the names and e-mail addresses of at least two potential referees (note that the editor retains the sole right to decide whether or not to use the people suggested). The author may also exclude a limited number of researchers as potential reviewers of the manuscript (maximum two people).

Editorial Office Assessment

The Editorial Office will check whether the composition and format of the paper comply with the Guide for Authors, to ensure it includes the required sections and styles. If the manuscript fails to meet one or more requirements, the Editorial Office will return it to the authors for amendments.

Evaluation by the Editor-in-Chief (EIC) and Assignment to an Associate Editor (AE)

The EIC performs pre-screening and may reject papers upfront and decide not to forward them to the peer-review process. This may occur in the case of submission of clearly plagiarized or previously published papers, as well as of papers that fall outside the scope of the Journal, are not innovative, or are of low relevance for readers.
The study must meet all ethical requirements as outlined in the Journal’s Publication Ethics.
If the manuscript meets all requirements, the EIC will assign it to an Associate Editor with relevant expertise, who will be responsible for managing the peer-review process. Associate Editors may reject manuscripts that they deem highly unlikely to pass peer review.

Invitation to Reviewers and Response

JPADR operates a single-blind review process. The quality of manuscript content is assessed by the AE and a minimum of two additional independent expert reviewers.
The handling AE sends invitations to individuals he/she maintains would be appropriate reviewers. Potential reviewers consider the invitation in light of their own expertise, conflicts of interest, and availability and are free to accept or decline the invitation. If possible, when declining, they may also suggest alternative reviewers.
As responses are received, further invitations are issued, if necessary, until the required number of reviewers is obtained.


The reviewers will rate several aspects of the manuscript, offer specific suggestions for improvement, and make a recommendation with regard to its suitability for publication. They are required to possess specific expertise in the field of individual submission, have time to produce a report within the deadline established by the editor, and be devoid of any conflict of interest with the Authors or the content of the submission.
They are expected to be balanced and consistently fair in evaluating papers and their reports should be analytical and constructive.
The review is submitted to the journal, with a recommendation to accept or reject the paper or with a request for revision (major or minor), that should be well substantiated and justified.
If major issues are identified on first reading the manuscript, the reviewer may decide to reject the paper without further input.
All information contained in the manuscript and acquired during the review process will be held in the strictest confidence.

AE evaluates the Reviews and makes a Decision

The handling AE considers all reviews received before making an overall decision. If the reviews differ considerably, the AE may invite additional reviewers in order to obtain further opinions before making a decision. The key parameters to be applied in the final evaluation of all types of submissions are:

  • Innovation (Is the manuscript original? Does it provide new evidence or ideas capable of furthering knowledge in the given social-economic context?)
  • Quality (clarity, logic, English language and grammar, thoroughness, layout, etc.)
  • Relevance (interest to readers, not too specific, applicability, the importance of the topic, impact on social life, economy, the scientific community, etc.)

Four possible decisions may therefore be reached:

  • Accept – the manuscript satisfies all publication parameters and is worthy of publication
  • Minor/Major Revisions – further revision of the manuscript is required in order to satisfy all parameters (a deadline for submission of the revised version is set)
  • Reject and Resubmission Suggested – the paper fails to satisfy key parameters and substantial revision of the manuscript is required to address its shortcomings (no deadlines are set)
  • Reject – the paper fails to satisfy key parameters and it is highly unlikely that further work can address its shortcomings.

Confirmation of the Decision and Communication to the Authors

All decisions are confirmed by the EIC prior to notification.
The Editorial Office sends a decision email to the corresponding author including any relevant reviewer comments. All comments and related files will be provided in an anonymized form.

Final Steps

If accepted, the paper is sent to production. Reviewers will receive an email informing them of the outcome of their review. JPADR will make every effort to ensure articles are published rapidly and accurately: the corresponding author will receive an e-mail with a link to the online proofing system (implementation in progress), and he/she should submit all corrections within 48 hours. Following the implementation of the corrections and signing of the Copyright Assignment by the authors, the article is published online under the license Creative Commons Attribution-NonCommercial – NoDerivs Alike (CC-BY-NC-ND).

Copyright for commercial and associated uses will remain with the Publisher.

If the article is returned to the authors for major or minor revision, the Editorial Office will provide constructive comments from the reviewers to help the author improve the article and set a deadline for submission of the revised manuscript. Whenever possible, the revised manuscript will be assessed by the original AE and by the original reviewers. Should only minor changes be requested this follow-up review may be performed directly by the AE.

If rejected, the paper is removed from the online system. Reviewers will receive an email informing them of the final decision.


If the author believes that the editorial decision reached for the manuscript is not fair, he/she may contact the Editorial Office at editor@jpadr.com, stating the manuscript number and describing in detail the reasons for the appeal. The EIC will evaluate all requests and make a final decision, consulting the handling AE and revising the previous decision, if necessary.

Errata and Corrigenda

JPADR will publish corrections to the article if significant errors are discovered after publication. An Erratum will be published in the Journal is responsible for the error, whilst a Corrigendum will be provided if the author is responsible.


Articles may be withdrawn, retracted, removed, or replaced after publication if they contain substantial errors that cannot be corrected by publishing an Erratum or a Corrigendum, or if ethical violations become known after publication. For more information, please visit our Publication Ethics

Copy right and permission

All materials published by JPADR Journal are subject to applicable copyright laws.  In submitting a manuscript to a JPADR journal, an author represents that all included materials are the author’s own work unless clearly otherwise identified. To avoid any potential issues with plagiarism (i.e., representing someone else’s work or ideas as one’s own) or copyright infringement (i.e., violating the exclusive copyright rights of another) or any other violation of the rights of other parties (including, but not limited to, personal rights, an expectation of privacy, or other confidentiality requirements), authors should clearly identify any third-party materials and their respective rights holders in their submissions.  The author shall additionally ensure that any needed permissions are secured and provided to the journal with their accepted article. While authors are responsible for obtaining all permissions and other releases for third-party materials, JPADR is happy to provide guidance on copyright permissions and other rights releases. If you don’t see your question addressed below, you can contact the journal’s editor or production editor for additional clarification.


Facts and opinions in articles published in the Journal of Pharmacovigilance and Drug Research are solely the personal statements of respective authors.  Authors are responsible for all contents in their article(s) including accuracy of the facts, statements, citing resources, and so on. Journal of Pharmacovigilance and Drug Research and editors disclaim any liability of violations of other parties’ rights or any damage incurred as a consequence to use or applying any of the contents of the Journal of Pharmacovigilance and Drug Research. Manuscripts submitted to the Journal of Pharmacovigilance and Drug Research must be original and not published or submitted for publication elsewhere. Authors submitting a contribution to the Journal of Pharmacovigilance and Drug Research who have related manuscripts under consideration or in press elsewhere should upload a clearly marked copy at the time of submission and draw the editor’s attention to it in their cover letter. If a part of a contribution that an author wishes to submit to the Journal of Pharmacovigilance and Drug Research has appeared or will appear elsewhere, the author must specify the details in the cover letter. Consideration by the Journal of current research in science is possible if the main result, conclusion, or implications are not apparent from the other work, or if there are other factors, for example, if the other work is published in a language other than English. The author is responsible to get permission from the previous publisher or copyright holder if an author is re-using any part of the paper (i.e. figure or figures) published elsewhere, or that is copyrighted. The editors consider all material in good faith that their journals have full permission to publish every part of the submitted material including illustrations.

Plagiarism Policy
The Editorial Team of the Journal of Pharmacovigilance and Drug Research takes the necessary measures to examine the incoming papers on their originality, reliability of contained information, and correct use of citations. The Editorial Team of the Journal of Pharmacovigilance and Drug Research acknowledges that plagiarism is unacceptable and therefore establishes the following policies for publication in the Journal of Pharmacovigilance and Drug Research.
Authors should ensure that they submit only entirely original works. If they have used the work and/or statements of others, this must be appropriately cited or referenced. Plagiarism in any form, including quotations or paraphrasing of substantial parts of another’s article (without attribution), “passing off” another’s article as the author’s own, or claiming results from research conducted by others, constitutes unethical publishing behavior and is unacceptable. Manuscripts that are a compilation of previously published materials of other authors (without their own creative and authoring interpretation) are not accepted for publication.
It is inadmissible to use unfair text borrowing and assigning research results not belonging to the authors of the submitted manuscript.
The authors must ensure that the submitted manuscript:
- describes completely the original work;
- is not plagiarism;
- has not been published before in any language;
- the information used or words from other publications are appropriately indicated by reference or indicated in the text.
Existing copyright laws and conventions must be observed. Materials protected by copyright (for example, tables, figures, or large quotations) should only be reproduced with the permission of their owner.
The Journal of Pharmacovigilance and Drug Research takes responsibility to assist a scientific community in all aspects of publication ethics policy, particularly in case of multiple submission/publication and plagiarism. The editors reserve the right to check the received manuscripts for plagiarism.
The manuscript submitted to the Journal of Pharmacovigilance and Drug Research must have a similarity level of less than 10%. Similarity per each detected reference also must be a maximum of 1%. The textual similarity in the amount of more than 10% is unacceptable.
The Policy of Screening for Plagiarism
All manuscripts must be free from plagiarism contents. All authors are suggested to use plagiarism detection software to do the similarity checking. Editors check the plagiarism detection of manuscripts in this Journal of Pharmacovigilance and Drug Research by using Grammarly detection software (www.grammarly.com) and using iThenticate since September 2019. The Journal of Pharmacovigilance and Drug Research will immediately reject papers leading to plagiarism or self-plagiarism.
The Journal of Pharmacovigilance and Drug Research adheres to international practices of preventing plagiarism. Thus, all authors that submit their manuscripts to the Journal of Pharmacovigilance and Drug Research must check that their academic work respects the copyrights of other scholars and avoids any and all plagiarism. Once the manuscript is submitted to the Journal of Pharmacovigilance and Drug Research, the editorial team will assign a group of anti-plagiarism members to check the manuscript through various tools. If proof of plagiarism is found, the manuscript will be rejected immediately, and the Editorial Board will communicate with the author to demand an explanation and the amendment of the plagiarized content. If the author does not respond within a reasonable length of time or does not make the necessary adjustments, they will not be able to submit manuscripts to the Journal of Pharmacovigilance and Drug Research for a period of five (5) years. If the Editorial Board has reason to believe that the manuscript was not drafted or researched in an ethical manner, the journal’s implemented code of ethics (Committee on Publication Ethics [Code of Conduct and Best Practices Guidelines for Journals Editors]) will be reviewed and act accordingly.
Definition of Plagiarism:
"Plagiarism is the use of others' published and unpublished ideas or words (or other intellectual property) without attribution or permission, and presenting them as new and original rather than derived from an existing source. The intent and effect of plagiarism is to mislead the reader as to the contributions of the plagiarizer. This applies whether the ideas or words are taken from abstracts, research grant applications, Institutional Review Board applications, or unpublished or published manuscripts in any publication format (print or electronic). Plagiarism is scientific misconduct and should be addressed as such. Self-plagiarism refers to the practice of an author using portions of their previous writings on the same topic in another of their publications, without specifically citing it formally in quotes. This practice is widespread and sometimes unintentional, as there are only so many ways to say the same thing on many occasions, particularly when writing the Methods section of an article. Although this usually violates the copyright that has been assigned to the publisher, there is no consensus as to whether this is a form of scientific misconduct, or how many of one's own words one can use before it is truly "plagiarism." Probably for this reason self-plagiarism is not regarded in the same light as plagiarism of the ideas and words of other individuals. If journals have developed a policy on this matter, it should be clearly stated for authors." (WAME, 2020).
Direct plagiarism is the plagiarism of the text. Mosaic plagiarism is the borrowing of ideas and opinions from an original source and a few verbatim words or phrases without crediting the author. Plagiarism is committed when one author uses another work (typically the work of another author) without permission, credit, or acknowledgment. Plagiarism takes different forms, from literal copying to paraphrasing the work of another.
Authors can adhere to the following steps to report plagiarism:

  • Inform the editor of the Journal of Pharmacovigilance and Drug Research where a plagiarized paper is published.
  • Send original and plagiarized papers with plagiarized parts highlighted.
  • If evidence of plagiarism is convincing, an editor should arrange for a disciplinary meeting.
  • Editor of the Journal of Pharmacovigilance and Drug Research where the plagiarized paper should communicate with the editor of the Journal of Pharmacovigilance and Drug Research containing the original paper to rectify the matter.
  • The plagiarist should be asked to provide an explanation.
  • In case of nonresponse in the stipulated time or an unsatisfactory explanation, the paper should be permanently retracted.
  • The author should be blacklisted and debarred for submitted a paper to a particular journal for at least 5 years.
  • The concerned head of the institution has to be notified.

The author bears the responsibility for checking whether material submitted is subject to copyright or ownership rights, e.g. figures, tables, photographs, illustrations, trade literature, and data. The author will need to obtain permission to reproduce any such items and include these permissions with their final submission. Where use is so restricted, the editorial office and Publisher must be informed with the final submission of the material. Please add any necessary acknowledgments to the typescript, preferably in the form of an Acknowledgments section at the end of the paper. Credit the source and copyright of photographs, figures, illustrations, etc. in the supplementary captions.
Plagiarism is an act intentionally or unintentionally in obtaining or trying to obtain credit or value for scientific work, by quoting part or all of the work and/or scientific work of other parties that are recognized as scientific works, without expressing the source appropriately and adequately. Therefore, manuscripts must be original, never published, and not in the process of waiting for publication elsewhere. Material taken verbally from other sources needs to be clearly identified so that it is different from the original text.
If plagiarism is identified, the Editor-in-Chief is responsible for reviewing the manuscript and will approve the action in accordance with the level of plagiarism detected, with the following guidelines:
Plagiarism Level
1. Tracing a portion of a short sentence from another paper without mentioning the source.
     Action: Authors are given warnings and requests to change the text and quote correctly.
2. Tracing most of the other papers without the right quote and not mentioning the source.
     Actions: The submitted manuscript is rejected for publication in the Journal of Pharmacovigilance and Drug Research and the Author can be sanctioned for not being allowed to publish in the Journal of Pharmacovigilance and Drug Research.
3. All manuscript writers are responsible for the content of manuscripts they submit to the Journal of Pharmacovigilance and Drug Research. If the manuscript is classified as plagiarism, then all authors will be subject to the same action.
4. If the author is proven to submit the manuscript to the Journal of Pharmacovigilance and Drug Research by simultaneously sending it to another journal, and this overlap is found during the reviewer process or after publication, then the action according to point 2 above is given.
5. If plagiarism is found outside the rules above, the editor of the Journal of Pharmacovigilance and Drug Research has the right to give sanctions according to the editor's team policy.
6. In case of multiple borrowing Editorial Board acts according to the rules of COPE.
There are several indicators of plagiarism that all authors must be aware of:
1. The most easily identifiable plagiarism is that of repeated content when an author copies another author's work by reciting words, sentences, or paragraphs without citing original sources. This plagiarism model can be easily identified by our plagiarism checker software.
2. The second type of plagiarism occurs when an author reproduces a substantial part of another writer's work, without citing him/her. The term "reproducing substance" here can be understood as copying another's ideas, both in terms of quantity and quality, which potentially eliminates the original author's rights, in the context of intellectual property.
3. The third type of plagiarism is when an author takes ideas, words, or phrases in paraphrased sentences or paragraphs, without citing the original source. This type of plagiarism often cannot be checked through plagiarism software, as it is idea-based. Yet, this practice becomes unethical when the author does not cite, nor acknowledge the original source from the original writer.

Archive Policy

The articles published in the Journal of Pharmacovigilance and Drug Research can be archived through the following link. https://jpadr.com/index.php/jpadr/issue/archive

JPADR has electronic backup and preservation of access to the content of its journals via PKP Preservation Network (PKP PN).

PKP has developed the PKP Preservation Network (PKP PN) to digitally preserve OJS journals. The LOCKSS program offers decentralized and distributed preservation, seamless perpetual access, and preservation of the authentic original version of the content. The PKP PN ensures that journals that are not part of any other digital preservation service (such as CLOCKSS or Portico) can be preserved for long-term access. For additional details about the PKP PN, see the high-level overview (an early discussion document).

Journal is also indexed with PKP INDEX. All URLs are OAI qualified.

Public Knowledge Project has developed the PKP Preservation Network (PKP PN) to digitally preserve journals, PKP PN stores, and distribute all journal content at participating libraries.